Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.79B | 2.75B | 2.50B | 2.00B | 1.37B |
Gross Profit | 420.37M | 446.95M | 472.32M | 412.59M | 289.88M |
EBITDA | 4.88M | -23.33M | 157.50M | 146.77M | 148.22M |
Net Income | -201.28M | -204.46M | -1.84M | 31.96M | 88.84M |
Balance Sheet | |||||
Total Assets | 1.65B | 1.77B | 1.94B | 2.03B | 1.43B |
Cash, Cash Equivalents and Short-Term Investments | 112.58M | 2.22M | 14.45M | 133.14M | 183.28M |
Total Debt | 1.30B | 1.14B | 1.02B | 1.02B | 517.74M |
Total Liabilities | 1.69B | 1.61B | 1.59B | 1.65B | 1.01B |
Stockholders Equity | -38.47M | 156.19M | 354.56M | 373.27M | 411.61M |
Cash Flow | |||||
Free Cash Flow | -34.04M | -125.26M | -43.45M | 165.52M | 336.29M |
Operating Cash Flow | -6.41M | -82.97M | -10.44M | 186.84M | 348.44M |
Investing Cash Flow | -27.63M | -42.29M | -111.81M | -685.63M | -635.01M |
Financing Cash Flow | 144.37M | 113.07M | 3.81M | 448.85M | 408.26M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $1.56B | 11.81 | 8.15% | 2.00% | -16.10% | -48.97% | |
69 Neutral | $1.65B | 15.86 | 10.65% | 2.30% | 25.19% | 13.44% | |
48 Neutral | $33.59M | ― | -951.52% | ― | -0.70% | -2.38% | |
48 Neutral | $715.51M | 18.62 | -40.13% | ― | -14.33% | -398.68% | |
47 Neutral | $1.50B | 94.15 | 42.49% | ― | 11.53% | ― | |
47 Neutral | C$213.29M | -1.44 | -30.58% | 3.10% | 19.48% | -0.04% | |
45 Neutral | $426.23M | ― | -1.96% | ― | -24.30% | -210.27% |
On July 10, 2025, Modivcare Inc. announced it regained compliance with Nasdaq’s Rule 5450(b)(3)(C) regarding the market value of publicly held shares, ensuring continued listing on The Nasdaq Global Select Market. This compliance was confirmed on July 7, 2025, after the company’s market value exceeded $15 million for 20 consecutive business days, reflecting positively on its stock performance and enterprise value efforts.
The most recent analyst rating on (MODV) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on ModivCare stock, see the MODV Stock Forecast page.
On June 17, 2025, ModivCare Inc. held its annual meeting of stockholders where all proposed measures were approved, and the recommended director nominees were elected for a one-year term. The meeting also saw the approval of the executive officer compensation and the ratification of KPMG LLP as the independent registered public accounting firm for the 2025 fiscal year.
The most recent analyst rating on (MODV) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on ModivCare stock, see the MODV Stock Forecast page.